COSCIENS Biopharma Inc.
CSCI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.02 | 0.09 | 0.05 |
| FCF Yield | -219.98% | -22.52% | 32.95% | 15.80% |
| EV / EBITDA | 0.51 | -3.41 | 1.09 | 2.36 |
| Quality | ||||
| ROIC | -92.93% | -16.03% | 15.55% | 14.61% |
| Gross Margin | 49.33% | 41.13% | 58.72% | 60.87% |
| Cash Conversion Ratio | 0.95 | 0.74 | 1.52 | 1.04 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.84% | -19.09% | 7.11% | 11.00% |
| Free Cash Flow Growth | -376.06% | -167.09% | 124.14% | -26.92% |
| Safety | ||||
| Net Debt / EBITDA | 1.04 | 1.75 | -1.34 | -0.96 |
| Interest Coverage | -203.73 | -34.04 | 30.21 | 20.38 |
| Efficiency | ||||
| Inventory Turnover | 2.60 | 1.05 | 2.17 | 72.38 |
| Cash Conversion Cycle | 80.28 | 362.81 | 221.20 | 50.44 |